In Systemic Medicine and the Eye Longevity approach, Glaucoma is no longer seen as a purely "hydraulic" disease driven only by high Intraocular Pressure (IOP), but is framed as a chronic optic neuropathy with neurodegenerative and neurovascular components. The central process is the progressive suffering and loss of Retinal Ganglion Cells (RGCs) at the level of the lamina cribrosa. This helps explain why a proportion of patients can show progression despite IOP values within the normal range (Normal Tension Glaucoma – NTG). IOP control nevertheless remains the cornerstone of therapy; neurodegenerative and hemodynamic aspects are fields of research and integration, not alternatives to conventional pressure‑lowering treatments.

Interact with the cards below: risk factors tend to increase the overall stress load on the eye, while systemic interventions aim to reduce it and support the optic nerve. This is a simplified scheme for educational and informational purposes.

Energy and Metabolic Imbalance

The engine of vulnerability. Visual neurons have a very high energy demand (ATP). When mitochondrial function declines and cellular cleaning systems (autophagy) are not efficient, susceptibility to damage increases. This can be associated with a dysmetabolic profile (diabetes, obesity, insulin resistance) that gradually impairs the supporting microcirculation.

Vascular Dysregulation and Posture

Silent hypoxia. In some forms, especially normal-tension glaucoma, patients often show low systemic blood pressure (particularly at night), cold extremities, and sleep-disordered breathing (OSAS). Suboptimal vascular autoregulation may favor episodes of hypoxia. Chronic postural alterations may represent an additional general factor to consider, although they should not be interpreted as a direct standalone cause of glaucoma.

Stress-related and Toxic Profile

Low-grade neuroinflammation. Chronic stress, non-restorative sleep, and systemic toxin load (such as smoking) may promote activation of microglia toward a pro‑inflammatory profile. Over time, this cytokine release may contribute to increased vulnerability of optic nerve fibers. The possible role of gut dysbiosis is also an emerging research hypothesis, but it remains under investigation.

Supportive Neuroprotection

Supportive neuroprotection. Several nutraceuticals have been investigated for their potential role in supporting mitochondrial metabolism and synaptic stability. Molecules such as citicoline and coenzyme Q10 are discussed in the literature as possible adjuvants to help sustain ganglion cell function over time, always and only in addition to conventional IOP‑lowering therapies, when deemed appropriate by the specialist.

Pro‑Longevity Module

Sirtuins and mitophagy. Tight glycemic control and, in selected cases, interventions on meal timing (such as overnight intermittent fasting, only if explicitly agreed upon with the physician) are being studied for their ability to modulate longevity genes and mitophagy (removal of defective mitochondria). These are evolving research areas that do not in any way replace standard treatments and should only be considered within individualized care plans agreed upon with the attending physician or specialist.

Hemodynamic Optimization

Oxygenation and rebalancing. Managing sleep apnea where present, engaging in tailored aerobic exercise, and addressing selected general contributing factors may help improve oxygen delivery to ocular tissues. Antioxidants are also being studied for their possible role in counteracting oxidative stress that, over time, may contribute to lamina cribrosa remodeling.

Medical and Ethical Disclaimer

The contents of this page are intended strictly for educational purposes. The systemic and neuroprotective strategies described may complement but in no way replace an ophthalmological examination or conventional IOP‑lowering therapies (eye drops, laser, surgery), which remain essential for disease control. All treatment choices must be evaluated and agreed upon with a specialist.
The information on this page is provided for general educational purposes only.
It does not replace an eye examination, a specialist consultation, a medical diagnosis, or an individualized treatment plan.
Any decision regarding medications, supplements, surgery, lifestyle changes, or diagnostic tests must be taken together with your own physician or eye specialist.
Any description of nutritional, integrative, or systemic strategies does not represent a standardized treatment protocol and must not be interpreted as an automatic recommendation for individual patients.
The strategies described are general in nature and do not constitute any form of individual therapeutic recommendation.

Verified Scientific References

Flammer J, et al. The impact of ocular blood flow in glaucoma. Progress in Retinal and Eye Research, 2002.
Osborne NN, et al. Mitochondria: Their role in ganglion cell death and survival in primary open angle glaucoma. Experimental Eye Research, 2004.
Parisi V, et al. Cytidine-5'-Diphosphocholine (Citicoline): a rationale for its clinical use in neuro-ophthalmology. European Journal of Ophthalmology, 2011.

Clinical Management of Glaucoma

Integrated diagnostic evaluation, IOP measurement, and optic nerve OCT.

info: medicioculisti.it